Mumbai, December 17, 2024 – Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine
Granules India Limited, a leading pharmaceutical company, is thrilled to announce that it has received the Golden Peacock Award for Sustainability. This esteemed award was presented at the Institute of Directors’ Annual Global Convention on Corporate Governance & Sustainability being held in London, UK, and
Granules India Limited, a leading pharmaceutical manufacturing company, is pleased to announce that it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Unit V facility located at Jawaharlal Nehru Pharma City (JNPC), Anakapalli District, Parawada Mandal,
Quote for International Women’s Day from Priyanka Chigurupati, Executive Director, Granules India Ltd. "As we commemorate International Women's Day, it's important to recognize the strides we have made towards gender equality yet acknowledge that we have miles to go. In the pharmaceutical industry, we are at
Granules India Limited today announced that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Gabapentin Tablets USP, 600 mg and 800 mg. It is bioequivalent to the reference listed drug product (RLD), Neurontin Tablets, 600 mg and 800
